Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Plasmodium immunotherapy CAS Lamvac Biotech (Primary)
- Indications CNS cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors CAS Lamvac Biotech
- 17 Feb 2024 Planned End Date changed from 31 Oct 2021 to 31 Oct 2026.
- 17 Feb 2024 Planned primary completion date changed from 30 Jun 2021 to 30 Apr 2024.
- 20 Nov 2019 New trial record